Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2024-05-31 00:00:00 ET · period of report 2024-05-31 · accession 0000950170-24-067539 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-31 | 2024-05-31 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +7,500 | 249.6K | +3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stoock | 2024-05-31 | A | A | 7,500 | $0.00 | 249,567 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted on May 31, 2024. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of December 18, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |